title: Results of surgery after concurrent chemoradiotherapy in advanced cervical cancer: comparison of extended hysterectomy and extrafascial hysterectomy.
abstract: OBJECTIVE
  The primary objective of this study was to compare disease-free survival (DFS) and overall survival (OS) of patients with and without completion surgery. The secondary objective was to compare DFS and OS of patients who had had systematic simple extrafascial hysterectomy or extended hysterectomy. The other objectives were to compare early and late complications with and without completion surgery and between the various surgical techniques.
  
  
  METHODS
  One hundred seventy-one patients with advanced cervical cancer were included in a retrospective, multicenter series.
  
  
  RESULTS
  The rate of pelvic control was 81.29% in our study after chemoradiotherapy, but histological residual cervical tumor persisted in nearly half of cases (49.71%). After a mean follow-up of 33 months, OS and DFS were not significantly higher in surgically treated patients, nor was the complication rate higher. Overall survival and DFS were not better after radical hysterectomy than after extrafascial hysterectomy. Statistically significant predictors of survival were clinical stage, tumor size, node extension, and residual tumor after chemoradiotherapy.
  
  
  CONCLUSIONS
  There is no consensus regarding the maximal residual tumor volume after chemoradiotherapy suitable for surgery as there is no reliable imaging yet. Therefore, extrafascial hysterectomy with bilateral pelvic lymphadenectomy seems as a reasonable option if there are histological factors suggesting poor prognosis.
authors.affiliation: Service de Chirurgie Générale et Gynécologique, Centre Hospitalier et Universitaire Rangueil, Toulouse, France. mottonsteph@yahoo.fr
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Motton
authors.forename: Gilles
authors.initials: G
authors.lastname: Houvenaeghel
authors.forename: Martine
authors.initials: M
authors.lastname: Delannes
authors.forename: Denis
authors.initials: D
authors.lastname: Querleu
authors.forename: Marc
authors.initials: M
authors.lastname: Soulé-Tholy
authors.forename: Jean
authors.initials: J
authors.lastname: Hoff
authors.forename: Pierre
authors.initials: P
authors.lastname: Lèguevaque
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010388:Pelvis; D011183:Postoperative Complications / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents